Contact

News

Stay up to date on ReAlta’s news, scientific progress, clinical milestones, and mission to address severe inflammatory disease.
Press Release
Apr 08, 2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

Press Release
Apr 08, 2026
ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)
Press Release
Mar 24, 2026
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO
Press Release
Jan 26, 2026
ReAlta Life Sciences Announces Appointment of Kia Motesharei, Ph.D. to Board of Directors
Press Release
Jan 07, 2026
ReAlta Life Sciences Announces Appointment of Jonathan Rigby to Board of Directors
Press Release
Nov 25, 2025
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman
ABSTRACT
Jul 22, 2025
The Anti-inflammatory Peptide RLS-0071 Reduces Immune Cell Recruitment and Oxidative Damage in a Neonatal Rat Model of Hypoxic–Ischemic Encephalopathy
1 2 3 4